These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 24751371)

  • 21. Acute blistering disease presenting IgG autoantibodies against NC16A and COOH-terminal domains of BP180 and laminin-332, with characteristic distribution of eruptions.
    Kurashige Y; Minemura T; Nagatani T; Koga H; Hashimoto T
    Eur J Dermatol; 2013; 23(1):109-10. PubMed ID: 23306276
    [No Abstract]   [Full Text] [Related]  

  • 22. Orf-induced pemphigoid with antilaminin-332 antibodies.
    van den Bos RR; Middelburg T; van Biezen P; van der Eijk AA; Pas HH; Diercks GF
    Br J Dermatol; 2012 Oct; 167(4):956-8. PubMed ID: 22512910
    [No Abstract]   [Full Text] [Related]  

  • 23. Desmoglein1 and BP 180 ELISA indexes correlating with disease activity in a patient with coexisting pemphigus foliaceus and bullous pemphigoid.
    Ando S; Sato-Matsumura KC; Kasai M; Nemoto-Hasebe I; Hoshina D; Ohyama B; Hashimoto T; Shimuzu H
    Clin Exp Dermatol; 2009 Dec; 34(8):e995-6. PubMed ID: 20055881
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiplectin autoantibodies in subepidermal blistering diseases.
    Buijsrogge JJ; de Jong MC; Kloosterhuis GJ; Vermeer MH; Koster J; Sonnenberg A; Jonkman MF; Pas HH
    Br J Dermatol; 2009 Oct; 161(4):762-71. PubMed ID: 19566666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A vesicular variant of bullous pemphigoid with autoantibodies against unidentified 205- and 150-kDa proteins at the basement membrane zone.
    Satoh S; Seishima M; Izumi T; Ito A; Kamiya H; Kitajima Y
    Br J Dermatol; 1997 Nov; 137(5):768-73. PubMed ID: 9415239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunologic phenomena in the skin of patients with pemphigoid in relation to the pathologic process].
    Torzecka JD; Lutowiecka-Wranicz A; Sysa-Jedrzejowska A; Waszczykowska E; Dziankowska-Bartkowiak B
    Przegl Dermatol; 1988; 75(4):266-71. PubMed ID: 3070636
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevalence of autoantibodies to bullous pemphigoid antigens within the normal population.
    Fine JD
    Arch Dermatol; 2010 Jan; 146(1):74-5. PubMed ID: 20083697
    [No Abstract]   [Full Text] [Related]  

  • 28. Bullous pemphigoid initially localized around the surgical wound of an arthroprothesis for coxarthrosis.
    Lo Schiavo A; Caccavale S; Alfano R; Gambardella A; Cozzi R
    Int J Dermatol; 2014 Apr; 53(4):e289-90. PubMed ID: 24261580
    [No Abstract]   [Full Text] [Related]  

  • 29. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
    Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coexistence of psoriasis and linear IgA disease in a patient with recent herpes zoster infection.
    Cooke N; Jenkinson H; Wojnarowska F; McKenna K; Alderdice J
    Clin Exp Dermatol; 2005 Nov; 30(6):643-5. PubMed ID: 16197377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of IgG and IgE reactivity to BP180 using the ISAC® microarray system.
    Pomponi D; Di Zenzo G; Zennaro D; Calabresi V; Eming R; Zuzzi S; Bernardi ML; Scala E; Mari A
    Br J Dermatol; 2013 Jun; 168(6):1205-14. PubMed ID: 23252883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgA anti-p200 pemphigoid.
    Wozniak K; Hashimoto T; Fukuda S; Ohyama B; Ishii N; Koga H; Dainichi T; Kowalewski C
    Arch Dermatol; 2011 Nov; 147(11):1306-10. PubMed ID: 22106117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pemphigoid nodularis with diverse IgG, IgA and IgE antibodies showing neutrophilic papillary microabscesses.
    Asahina A; Niizuma A; Ohzono A; Ishii N; Koga H; Hashimoto T
    Acta Derm Venereol; 2015 Feb; 95(2):239-40. PubMed ID: 24854228
    [No Abstract]   [Full Text] [Related]  

  • 34. Case of burn-associated bullous pemphigoid caused by anti-BP230 immunoglobulin G autoantibodies.
    Morita R; Oiso N; Ishii N; Tatebayashi M; Matsuda H; Hashimoto T; Kawada A
    J Dermatol; 2015 Jun; 42(6):657-8. PubMed ID: 25809208
    [No Abstract]   [Full Text] [Related]  

  • 35. Significantly higher prevalence of circulating bullous pemphigoid-specific IgG autoantibodies in elderly patients with a nonbullous skin disorder.
    Meijer JM; Lamberts A; Pas HH; Jonkman MF
    Br J Dermatol; 2015 Nov; 173(5):1274-6. PubMed ID: 25912001
    [No Abstract]   [Full Text] [Related]  

  • 36. Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid.
    Li N; Culton D; Diaz LA; Liu Z
    J Invest Dermatol; 2018 Jun; 138(6):1249-1251. PubMed ID: 29793619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing the diagnostic sensitivity for mucous membrane pemphigoid by detection of salivary autoantibodies.
    Schmidt E
    Br J Dermatol; 2016 May; 174(5):956-7. PubMed ID: 27206357
    [No Abstract]   [Full Text] [Related]  

  • 38. Bullous Pemphigoid with Immunoglobulin G anti-LAD-1 Antibodies without Evident Erythema and Eosinophil Infiltration.
    Ikawa T; Tada Y; Ohnishi T; Miyagaki T; Watanabe R; Ishii N; Hashimoto T; Watanabe S
    Acta Derm Venereol; 2016 Aug; 96(6):832-3. PubMed ID: 26976695
    [No Abstract]   [Full Text] [Related]  

  • 39. BP-180-specific IgG antibodies: A potential useful candidate for early diagnosis of Bullous pemphigoid during anti-PD-1/anti-PDL-1 of melanoma patients.
    Tsiakou A; Douvali T; Gregoriou S
    Med Hypotheses; 2021 Dec; 157():110703. PubMed ID: 34670173
    [No Abstract]   [Full Text] [Related]  

  • 40. Epitope spreading in bullous pemphigoid: what does it mean?
    Miner A; Kirsner RS
    J Invest Dermatol; 2011 Nov; 131(11):2165. PubMed ID: 21997414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.